Oberfield J L, Collins J L, Holmes C P, Goreham D M, Cooper J P, Cobb J E, Lenhard J M, Hull-Ryde E A, Mohr C P, Blanchard S G, Parks D J, Moore L B, Lehmann J M, Plunket K, Miller A B, Milburn M V, Kliewer S A, Willson T M
Department of Molecular Endocrinology, Glaxo Wellcome Research and Development, Research Triangle Park, NC 27709, USA.
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6102-6. doi: 10.1073/pnas.96.11.6102.
The peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that regulate glucose and lipid homeostasis. The PPARgamma subtype plays a central role in the regulation of adipogenesis and is the molecular target for the 2, 4-thiazolidinedione class of antidiabetic drugs. Structural studies have revealed that agonist ligands activate the PPARs through direct interactions with the C-terminal region of the ligand-binding domain, which includes the activation function 2 helix. GW0072 was identified as a high-affinity PPARgamma ligand that was a weak partial agonist of PPARgamma transactivation. X-ray crystallography revealed that GW0072 occupied the ligand-binding pocket by using different epitopes than the known PPAR agonists and did not interact with the activation function 2 helix. In cell culture, GW0072 was a potent antagonist of adipocyte differentiation. These results establish an approach to the design of PPAR ligands with modified biological activities.